Societe Generale Downgrades Mead Johnson Nutrition (MJN) to Hold

Go back to Societe Generale Downgrades Mead Johnson Nutrition (MJN) to Hold

BMO Capital Remains Bullish on Mead Johnson (MJN) Following 2Q Report

July 29, 2016 9:22 AM EDT

BMO Capital reiterated an Outperform rating with a $97.00 price target on Mead Johnson Nutrition (NYSE: MJN) following the company's 2Q earnings report. MJN reported EPS of $0.88, above $0.81 estimates. The company reiterated EPS guidance of $3.48-3.60.

Analyst Amit Sharma commented, "MJN reported 2Q16 adjusted EPS of $0.88,... More

Mead Johnson (MJN) Tops Q2 EPS by 10c, Sales Miss; Reaffirms EPS Outlook

July 28, 2016 7:43 AM EDT

Mead Johnson (NYSE: MJN) reported Q2 EPS of $0.88, $0.10 better than the analyst estimate of $0.78. Revenue for the quarter came in at $941.5 million versus the consensus estimate of $963.66 million.

"As we move through this year, I am pleased that we continue to deliver against our... More